fool.com · 2 jul

Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say.

Axsome specializes in central nervous system disorders, including depression, migraine, and fibromyalgia. Axsome's Auvelity recently won approval to treat agitation associated with Alzheimer's disease.

forbes.com · 1 jul

Why Axsome Stock Has Doubled In Nine Months

In this week's edition of InnovationRx, we look at Axsome's growing pipeline, HistoSonics innovative cancer treatment, state litigation over Medicaid work requirements, and more. To get it in your inbox, subscribe here.

globenewswire.com · 26 jun

Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the FOCUS-3 Phase 3 trial evaluating solriamfetol as a treatment for adolescents with attention deficit hyperactivity disorder (ADHD).

globenewswire.com · 18 jun

Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month

NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining patients, caregivers, and advocacy organizations in raising awareness of brain health and the impact of Alzheimer's disease during Alzheimer's & Brain Awareness Month. “Nearly everyone knows brain health is important, but many people aren't sure what steps to take to protect it,” said Wendy Vizek, Senior Vice President, Community Engagement and Field Operations at the Alzheimer's Association.

fool.com · 16 jun

3 Under-the-Radar Stocks to Buy and Hold for a Decade

All three could become highly prominent biotech companies within 10 years.

globenewswire.com · 15 jun

Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data on AXS-12 and solriamfetol at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), being held June 14-17, 2026, in Baltimore, Maryland.

seekingalpha.com · 8 jun

Axsome Therapeutics, Inc. (AXSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Axsome Therapeutics, Inc. (AXSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

marketbeat.com · 6 jun

Axsome Therapeutics Readies Auvelity Alzheimer's Agitation Launch, Expands CNS Pipeline

Axsome Therapeutics NASDAQ: AXSM executives said the company is preparing to launch Auvelity in Alzheimer's disease agitation this month while continuing to expand the drug's use in major depressive disorder and advance a broad central nervous system pipeline.